|
|
| | (S)-BAY-293 Basic information |
| Product Name: | (S)-BAY-293 | | Synonyms: | (S)-BAY-293;BAY 293 Negative Control;4-Quinazolinamine, 6,7-dimethoxy-2-methyl-N-[(1S)-1-[4-[2-[(methylamino)methyl]phenyl]-2-thienyl]ethyl]-;BAY 294 | | CAS: | 2244904-69-4 | | MF: | C25H28N4O2S | | MW: | 448.58 | | EINECS: | | | Product Categories: | | | Mol File: | 2244904-69-4.mol |  |
| | (S)-BAY-293 Chemical Properties |
| Boiling point | 553.4±50.0 °C(Predicted) | | density | 1.218±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 9.61±0.10(Predicted) | | form | Solid | | color | White to off-white | | Optical Rotation | [α]/D +86.0 to +106.0°, c =1.0 in DMSO | | InChIKey | WEGLOYDTDILXDA-HNNXBMFYSA-N | | SMILES | C[C@@H](C1=CC(C2=CC=CC=C2CNC)=CS1)NC3=C4C=C(C(OC)=CC4=NC(C)=N3)OC |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | (S)-BAY-293 Usage And Synthesis |
| Uses | (S)-BAY-293 is a negative control of BAY 293. BAY 293 is a potent KRAS-SOS1 interaction inhibitor[1]. | | Biological Activity | BAY-294 corresponds to the (S)-enantiomer of and the recommended control for the selective SOS1-KRAS interaction inhibitor BAY-293 (IC50 = 2.34 μM/BAY-294 vs. 21 nM/BAY-293; 10 nM hSOS1c at & 5 nM hKRAS G12C). BAY-294 exhibits little potency against SOS1-mediated KRAS activation (IC50 = 3.91 μM/BAY-294 vs. 52 nM/BAY-293; 10 nM SOS1c at & 50 nM wt hKRAS). | | storage | Store at -20°C | | References | [1] Hillig RC, et, al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560. DOI:10.1073/pnas.1812963116 |
| | (S)-BAY-293 Preparation Products And Raw materials |
|
|
Tag:(S)-BAY-293(2244904-69-4)
Related Product Information
|
|
BAY-293
(S)-BAY-293
2-Propen-1-one, 1-[(3S)-4-[(7R)-7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl]-6-chloro-8-fluoro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-quinazolinyl]-3-methyl-1-piperazinyl]-
2,7-Diazaspiro[4.4]nonane-2-acetamide, α-cyclopentyl-7-[[(2R,3R)-3-cyclopropyl-1-methyl-2-aziridinyl]carbonyl]-N-[(1R,10S,12S,18S)-1-[5-(4-cyclopropyl-1-piperazinyl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-2,7,8,10,11,12,13,16,17,18,19,21,22,23-tetradecahydro-22,22-dimethyl-13,19-dioxo-2-(2,2,2-trifluoroethyl)-15H-3,5-etheno-14,18-imino-6,10-methano-6H-pyrrolo[3,4-g][1,12,4,18]dioxadiazacyclodocosin-12-yl]-, (αS,5S)-
Y-27632
1,4-Oxazepin-5(2H)-one, 4-[3-[[2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]tetrahydro-
|